TLX Stock Analysis: Buy, Sell, or Hold?
TLX - Telix Pharmaceuticals Limited American Depositary Shares
$7.28
-0.47 (-6.06%)
▼
BUY
MODERATE Confidence
Last Updated: January 30, 2026
Earnings: Feb 19, 2026
17d
Get Alerted When TLX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 1.7% decline. Moderate conviction.
💡 BUY OPPORTUNITY: TLX shows positive signals but monitor for confirmation. Market pricing in 1.7% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$14.91
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$9.26
21.4% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TLX is currently trading at $7.28, which is considered oversold relative to its 30-day fair value range of $7.42 to $7.92. The stock's valuation (Forward PE: 20.2) is in line with its historical norms (21.3). Remarkably, the market is currently pricing in an annual earnings decline of 1.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $7.16. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.89 (+187.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, TLX is in a strong downtrend. The price is currently testing key support at $7.16. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.1% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.89 (+187.0%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$7.42 -
$7.92
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.1%)
- BULLISH: Trading 187.0% below Wall St target ($20.89)
Fair Price Analysis
30-Day Fair Range
$7.42 -
$7.92
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$7.16
Resistance Level
$8.45
Current Trend
Strong Downtrend
Fundamental Context
Forward P/E (Next Year Est.)
20.25
Wall Street Target
$20.90
(+187.0%)
Revenue Growth (YoY)
58.9%
Profit Margin
1.6%
Valuation Discount vs History
-1.7% cheaper
PE vs Historical
20.3 vs 21.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.7%
(market-implied from PE analysis)
1-Year Target
$7.16
(-2%)
2-Year Target
$7.03
(-3%)
3-Year Target
$6.91
(-5%)
3-Yr Target (if PE normalizes)
(PE: 20→21)
$7.27
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.3, Growth: 2296.7%)
$27.06
(+272%)
Base:
(SPY PE: 20.3, Growth: 2296.7%)
$24.57
(+238%)
Bear:
(PE: 17.2, Growth: 2296.7%)
$20.88
(+187%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (70x PE), but valuation improves significantly next year (20x PE) as earnings recover.
Forward PE: 69.93 | Forward EPS (Implied): $0.10
Bull Case
$8.79
(+21%)
Analyst growth 15.0%, PE expands to 73.4
Base Case
$7.28
(0%)
Market implied 0.0%, PE stable at 69.9
Bear Case
$5.57
(-24%)
Severe decline -15.0%, PE contracts to 62.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.3 to 21.3
Stabilization Target:
$7.66
(+5.2%)
PE Expansion Potential:
+5.2%
Last updated: February 01, 2026 7:38 AM ET
Data refreshes hourly during market hours. Next update: 8:38 AM
Data refreshes hourly during market hours. Next update: 8:38 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TLX showing a specific setup today?
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$404 | 63 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$64 | 55 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$8 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$102 | 62 BUY |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$85 | 55 HOLD |
Advanced TLX Option Strategies
Professional options setups generated by AI based on today's TLX price and gamma walls.
